News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Major Influenza Pandemic Threat is now Preventable and Treatable with Canopus BioPharma, Inc.'s Aerosol Statin Formulation



5/12/2009 10:32:04 AM

LOS ANGELES--(BUSINESS WIRE)--Canopus BioPharma Inc. (OTCPK: CBIA) today announced it has commissioned a team of experts led by Dr. Akihiro Shimosaka, to assist with its plans for major collaborations to license, manufacture and distribute its H1N1 Swine flu statin antiviral. This team is currently in negotiations with the Office of Disease Control and Emergency Response, the CDC and the SFDA in China with a view to initiating large scale clinical trials and gaining marketing approval on behalf of Canopus BioPharma.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES